nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—HTR2C—Sorafenib—liver cancer	0.22	0.424	CbGbCtD
Maprotiline—CYP1A2—Sorafenib—liver cancer	0.08	0.154	CbGbCtD
Maprotiline—ABCB1—Sorafenib—liver cancer	0.0699	0.135	CbGbCtD
Maprotiline—CYP2D6—Sorafenib—liver cancer	0.0659	0.127	CbGbCtD
Maprotiline—ABCB1—Doxorubicin—liver cancer	0.0424	0.0819	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—liver cancer	0.04	0.0772	CbGbCtD
Maprotiline—Dysphagia—Sorafenib—liver cancer	0.00276	0.00896	CcSEcCtD
Maprotiline—Erectile dysfunction—Sorafenib—liver cancer	0.00254	0.00825	CcSEcCtD
Maprotiline—Weight decreased—Sorafenib—liver cancer	0.00249	0.00811	CcSEcCtD
Maprotiline—Infestation NOS—Sorafenib—liver cancer	0.00246	0.00799	CcSEcCtD
Maprotiline—Infestation—Sorafenib—liver cancer	0.00246	0.00799	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00244	0.00792	CcSEcCtD
Maprotiline—Acute coronary syndrome—Sorafenib—liver cancer	0.00242	0.00788	CcSEcCtD
Maprotiline—Neuropathy peripheral—Sorafenib—liver cancer	0.00241	0.00783	CcSEcCtD
Maprotiline—Myocardial infarction—Sorafenib—liver cancer	0.00241	0.00783	CcSEcCtD
Maprotiline—Bone marrow depression—Epirubicin—liver cancer	0.0024	0.00782	CcSEcCtD
Maprotiline—Stomatitis—Sorafenib—liver cancer	0.00239	0.00779	CcSEcCtD
Maprotiline—Jaundice—Sorafenib—liver cancer	0.00239	0.00779	CcSEcCtD
Maprotiline—Hepatobiliary disease—Sorafenib—liver cancer	0.00232	0.00756	CcSEcCtD
Maprotiline—Bone marrow depression—Doxorubicin—liver cancer	0.00222	0.00723	CcSEcCtD
Maprotiline—Dermatitis atopic—Epirubicin—liver cancer	0.00219	0.00713	CcSEcCtD
Maprotiline—Urinary tract disorder—Sorafenib—liver cancer	0.00218	0.00708	CcSEcCtD
Maprotiline—Urethral disorder—Sorafenib—liver cancer	0.00216	0.00703	CcSEcCtD
Maprotiline—Erythema multiforme—Sorafenib—liver cancer	0.00209	0.00678	CcSEcCtD
Maprotiline—Tinnitus—Sorafenib—liver cancer	0.00206	0.00669	CcSEcCtD
Maprotiline—Flushing—Sorafenib—liver cancer	0.00205	0.00666	CcSEcCtD
Maprotiline—Cardiac disorder—Sorafenib—liver cancer	0.00205	0.00666	CcSEcCtD
Maprotiline—Dermatitis atopic—Doxorubicin—liver cancer	0.00203	0.0066	CcSEcCtD
Maprotiline—Angiopathy—Sorafenib—liver cancer	0.002	0.00651	CcSEcCtD
Maprotiline—Mediastinal disorder—Sorafenib—liver cancer	0.00199	0.00646	CcSEcCtD
Maprotiline—Petechiae—Epirubicin—liver cancer	0.00197	0.00642	CcSEcCtD
Maprotiline—Arrhythmia—Sorafenib—liver cancer	0.00197	0.00641	CcSEcCtD
Maprotiline—Alopecia—Sorafenib—liver cancer	0.00195	0.00634	CcSEcCtD
Maprotiline—Malnutrition—Sorafenib—liver cancer	0.00192	0.00624	CcSEcCtD
Maprotiline—Delirium—Epirubicin—liver cancer	0.00189	0.00614	CcSEcCtD
Maprotiline—Dysgeusia—Sorafenib—liver cancer	0.00188	0.00611	CcSEcCtD
Maprotiline—Petechiae—Doxorubicin—liver cancer	0.00183	0.00594	CcSEcCtD
Maprotiline—Bone disorder—Epirubicin—liver cancer	0.0018	0.00584	CcSEcCtD
Maprotiline—Delirium—Doxorubicin—liver cancer	0.00175	0.00568	CcSEcCtD
Maprotiline—Dyskinesia—Epirubicin—liver cancer	0.00173	0.00562	CcSEcCtD
Maprotiline—Syncope—Sorafenib—liver cancer	0.00172	0.0056	CcSEcCtD
Maprotiline—Leukopenia—Sorafenib—liver cancer	0.00172	0.00559	CcSEcCtD
Maprotiline—Dysarthria—Epirubicin—liver cancer	0.00172	0.00558	CcSEcCtD
Maprotiline—Loss of consciousness—Sorafenib—liver cancer	0.00169	0.00549	CcSEcCtD
Maprotiline—Atrioventricular block—Epirubicin—liver cancer	0.00167	0.00544	CcSEcCtD
Maprotiline—Bone disorder—Doxorubicin—liver cancer	0.00166	0.00541	CcSEcCtD
Maprotiline—Hypertension—Sorafenib—liver cancer	0.00166	0.00539	CcSEcCtD
Maprotiline—Coordination abnormal—Epirubicin—liver cancer	0.00165	0.00537	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00162	0.00528	CcSEcCtD
Maprotiline—Ventricular tachycardia—Epirubicin—liver cancer	0.00162	0.00528	CcSEcCtD
Maprotiline—Dry mouth—Sorafenib—liver cancer	0.0016	0.0052	CcSEcCtD
Maprotiline—Dyskinesia—Doxorubicin—liver cancer	0.0016	0.0052	CcSEcCtD
Maprotiline—Dysarthria—Doxorubicin—liver cancer	0.00159	0.00516	CcSEcCtD
Maprotiline—Salivary hypersecretion—Epirubicin—liver cancer	0.00158	0.00513	CcSEcCtD
Maprotiline—Infection—Sorafenib—liver cancer	0.00156	0.00506	CcSEcCtD
Maprotiline—Atrioventricular block—Doxorubicin—liver cancer	0.00155	0.00503	CcSEcCtD
Maprotiline—Shock—Sorafenib—liver cancer	0.00154	0.00501	CcSEcCtD
Maprotiline—Nervous system disorder—Sorafenib—liver cancer	0.00154	0.005	CcSEcCtD
Maprotiline—Thrombocytopenia—Sorafenib—liver cancer	0.00153	0.00499	CcSEcCtD
Maprotiline—Coordination abnormal—Doxorubicin—liver cancer	0.00153	0.00497	CcSEcCtD
Maprotiline—Skin disorder—Sorafenib—liver cancer	0.00152	0.00495	CcSEcCtD
Maprotiline—Ventricular tachycardia—Doxorubicin—liver cancer	0.0015	0.00488	CcSEcCtD
Maprotiline—Salivary hypersecretion—Doxorubicin—liver cancer	0.00146	0.00474	CcSEcCtD
Maprotiline—Dyspepsia—Sorafenib—liver cancer	0.00138	0.00449	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Sorafenib—liver cancer	0.00135	0.0044	CcSEcCtD
Maprotiline—Fatigue—Sorafenib—liver cancer	0.00135	0.00439	CcSEcCtD
Maprotiline—Constipation—Sorafenib—liver cancer	0.00134	0.00436	CcSEcCtD
Maprotiline—Vascular purpura—Epirubicin—liver cancer	0.00132	0.00428	CcSEcCtD
Maprotiline—Gastrointestinal pain—Sorafenib—liver cancer	0.00128	0.00417	CcSEcCtD
Maprotiline—Hot flush—Epirubicin—liver cancer	0.00126	0.0041	CcSEcCtD
Maprotiline—Increased appetite—Epirubicin—liver cancer	0.00125	0.00408	CcSEcCtD
Maprotiline—Menopausal symptoms—Epirubicin—liver cancer	0.00125	0.00406	CcSEcCtD
Maprotiline—Urticaria—Sorafenib—liver cancer	0.00124	0.00405	CcSEcCtD
Maprotiline—Abdominal pain—Sorafenib—liver cancer	0.00124	0.00403	CcSEcCtD
Maprotiline—Body temperature increased—Sorafenib—liver cancer	0.00124	0.00403	CcSEcCtD
Maprotiline—Purpura—Epirubicin—liver cancer	0.00122	0.00397	CcSEcCtD
Maprotiline—Vascular purpura—Doxorubicin—liver cancer	0.00122	0.00396	CcSEcCtD
Maprotiline—Cerebrovascular accident—Epirubicin—liver cancer	0.0012	0.00391	CcSEcCtD
Maprotiline—Osteoarthritis—Epirubicin—liver cancer	0.00118	0.00383	CcSEcCtD
Maprotiline—Hot flush—Doxorubicin—liver cancer	0.00117	0.00379	CcSEcCtD
Maprotiline—Increased appetite—Doxorubicin—liver cancer	0.00116	0.00377	CcSEcCtD
Maprotiline—Menopausal symptoms—Doxorubicin—liver cancer	0.00116	0.00376	CcSEcCtD
Maprotiline—Purpura—Doxorubicin—liver cancer	0.00113	0.00368	CcSEcCtD
Maprotiline—Asthenia—Sorafenib—liver cancer	0.00112	0.00366	CcSEcCtD
Maprotiline—Cerebrovascular accident—Doxorubicin—liver cancer	0.00111	0.00362	CcSEcCtD
Maprotiline—Pruritus—Sorafenib—liver cancer	0.00111	0.0036	CcSEcCtD
Maprotiline—Ataxia—Epirubicin—liver cancer	0.00111	0.0036	CcSEcCtD
Maprotiline—Osteoarthritis—Doxorubicin—liver cancer	0.00109	0.00354	CcSEcCtD
Maprotiline—Liver function test abnormal—Epirubicin—liver cancer	0.00109	0.00354	CcSEcCtD
Maprotiline—Orthostatic hypotension—Epirubicin—liver cancer	0.00108	0.0035	CcSEcCtD
Maprotiline—Diarrhoea—Sorafenib—liver cancer	0.00107	0.00349	CcSEcCtD
Maprotiline—Breast disorder—Epirubicin—liver cancer	0.00106	0.00346	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00106	0.00345	CcSEcCtD
Maprotiline—Muscular weakness—Epirubicin—liver cancer	0.00104	0.00338	CcSEcCtD
Maprotiline—Dizziness—Sorafenib—liver cancer	0.00104	0.00337	CcSEcCtD
Maprotiline—Ataxia—Doxorubicin—liver cancer	0.00103	0.00333	CcSEcCtD
Maprotiline—Dysphagia—Epirubicin—liver cancer	0.00102	0.00331	CcSEcCtD
Maprotiline—Eosinophilia—Epirubicin—liver cancer	0.00101	0.00328	CcSEcCtD
Maprotiline—Liver function test abnormal—Doxorubicin—liver cancer	0.00101	0.00327	CcSEcCtD
Maprotiline—Vomiting—Sorafenib—liver cancer	0.000996	0.00324	CcSEcCtD
Maprotiline—Orthostatic hypotension—Doxorubicin—liver cancer	0.000996	0.00324	CcSEcCtD
Maprotiline—Rash—Sorafenib—liver cancer	0.000988	0.00321	CcSEcCtD
Maprotiline—Dermatitis—Sorafenib—liver cancer	0.000987	0.00321	CcSEcCtD
Maprotiline—Breast disorder—Doxorubicin—liver cancer	0.000985	0.0032	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000982	0.00319	CcSEcCtD
Maprotiline—Headache—Sorafenib—liver cancer	0.000982	0.00319	CcSEcCtD
Maprotiline—Pancytopenia—Epirubicin—liver cancer	0.000967	0.00314	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—liver cancer	0.000962	0.00313	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—liver cancer	0.000942	0.00306	CcSEcCtD
Maprotiline—Pollakiuria—Epirubicin—liver cancer	0.000941	0.00306	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—liver cancer	0.000933	0.00303	CcSEcCtD
Maprotiline—Nausea—Sorafenib—liver cancer	0.000931	0.00303	CcSEcCtD
Maprotiline—Photosensitivity reaction—Epirubicin—liver cancer	0.00093	0.00302	CcSEcCtD
Maprotiline—Weight increased—Epirubicin—liver cancer	0.000927	0.00301	CcSEcCtD
Maprotiline—Weight decreased—Epirubicin—liver cancer	0.000921	0.003	CcSEcCtD
Maprotiline—Infestation NOS—Epirubicin—liver cancer	0.000908	0.00295	CcSEcCtD
Maprotiline—Infestation—Epirubicin—liver cancer	0.000908	0.00295	CcSEcCtD
Maprotiline—Drowsiness—Epirubicin—liver cancer	0.000908	0.00295	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.0009	0.00293	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—liver cancer	0.000895	0.00291	CcSEcCtD
Maprotiline—Neuropathy peripheral—Epirubicin—liver cancer	0.00089	0.00289	CcSEcCtD
Maprotiline—Stomatitis—Epirubicin—liver cancer	0.000885	0.00288	CcSEcCtD
Maprotiline—Jaundice—Epirubicin—liver cancer	0.000885	0.00288	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—liver cancer	0.00087	0.00283	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—liver cancer	0.00086	0.0028	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—liver cancer	0.000859	0.00279	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—liver cancer	0.000858	0.00279	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—liver cancer	0.000852	0.00277	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—liver cancer	0.000847	0.00276	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—liver cancer	0.00084	0.00273	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—liver cancer	0.00084	0.00273	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—liver cancer	0.00084	0.00273	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000833	0.00271	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—liver cancer	0.000824	0.00268	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—liver cancer	0.000819	0.00266	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—liver cancer	0.000819	0.00266	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—liver cancer	0.000815	0.00265	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—liver cancer	0.000811	0.00264	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—liver cancer	0.000805	0.00262	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—liver cancer	0.000799	0.0026	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—liver cancer	0.000795	0.00258	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—liver cancer	0.000784	0.00255	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—liver cancer	0.000771	0.00251	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—liver cancer	0.000762	0.00248	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—liver cancer	0.00076	0.00247	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—liver cancer	0.000756	0.00246	CcSEcCtD
Maprotiline—Flushing—Epirubicin—liver cancer	0.000756	0.00246	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—liver cancer	0.000754	0.00245	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—liver cancer	0.00075	0.00244	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—liver cancer	0.000745	0.00242	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—liver cancer	0.00074	0.0024	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—liver cancer	0.000739	0.0024	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—liver cancer	0.000735	0.00239	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—liver cancer	0.000728	0.00237	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—liver cancer	0.00072	0.00234	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—liver cancer	0.000713	0.00232	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—liver cancer	0.00071	0.00231	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—liver cancer	0.000705	0.00229	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—liver cancer	0.000703	0.00229	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—liver cancer	0.0007	0.00228	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—liver cancer	0.0007	0.00228	CcSEcCtD
Maprotiline—Tension—Epirubicin—liver cancer	0.000696	0.00226	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—liver cancer	0.000695	0.00226	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—liver cancer	0.000689	0.00224	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—liver cancer	0.000684	0.00222	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—liver cancer	0.00068	0.00221	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—liver cancer	0.000674	0.00219	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—liver cancer	0.000669	0.00217	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—liver cancer	0.000666	0.00217	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—liver cancer	0.000657	0.00213	CcSEcCtD
Maprotiline—Agitation—Epirubicin—liver cancer	0.000652	0.00212	CcSEcCtD
Maprotiline—Tension—Doxorubicin—liver cancer	0.000644	0.00209	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—liver cancer	0.000643	0.00209	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—liver cancer	0.000638	0.00207	CcSEcCtD
Maprotiline—Syncope—Epirubicin—liver cancer	0.000636	0.00207	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—liver cancer	0.000635	0.00207	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—liver cancer	0.000627	0.00204	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—liver cancer	0.000624	0.00203	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—liver cancer	0.000619	0.00201	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—liver cancer	0.000615	0.002	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—liver cancer	0.000613	0.00199	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—liver cancer	0.000603	0.00196	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—liver cancer	0.000602	0.00196	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.0006	0.00195	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—liver cancer	0.000591	0.00192	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—liver cancer	0.000589	0.00191	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—liver cancer	0.000588	0.00191	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—liver cancer	0.000584	0.0019	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—liver cancer	0.00058	0.00189	CcSEcCtD
Maprotiline—Oedema—Epirubicin—liver cancer	0.000579	0.00188	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—liver cancer	0.000577	0.00188	CcSEcCtD
Maprotiline—Infection—Epirubicin—liver cancer	0.000575	0.00187	CcSEcCtD
Maprotiline—Shock—Epirubicin—liver cancer	0.00057	0.00185	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—liver cancer	0.000569	0.00185	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—liver cancer	0.000568	0.00185	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—liver cancer	0.000567	0.00184	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—liver cancer	0.000567	0.00184	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—liver cancer	0.000565	0.00184	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—liver cancer	0.000562	0.00183	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—liver cancer	0.00056	0.00182	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—liver cancer	0.000557	0.00181	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000555	0.0018	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—liver cancer	0.000547	0.00178	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—liver cancer	0.000541	0.00176	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—liver cancer	0.00054	0.00176	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—liver cancer	0.000536	0.00174	CcSEcCtD
Maprotiline—Infection—Doxorubicin—liver cancer	0.000532	0.00173	CcSEcCtD
Maprotiline—Shock—Doxorubicin—liver cancer	0.000527	0.00171	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—liver cancer	0.000525	0.00171	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—liver cancer	0.000525	0.00171	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—liver cancer	0.000524	0.0017	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—liver cancer	0.000523	0.0017	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—liver cancer	0.00052	0.00169	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—liver cancer	0.00052	0.00169	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—liver cancer	0.000518	0.00168	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—liver cancer	0.000515	0.00167	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—liver cancer	0.00051	0.00166	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—liver cancer	0.000501	0.00163	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—liver cancer	0.0005	0.00163	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—liver cancer	0.000499	0.00162	CcSEcCtD
Maprotiline—Constipation—Epirubicin—liver cancer	0.000495	0.00161	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—liver cancer	0.000485	0.00158	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—liver cancer	0.000481	0.00156	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—liver cancer	0.000477	0.00155	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—liver cancer	0.000476	0.00155	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—liver cancer	0.000474	0.00154	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—liver cancer	0.000472	0.00153	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000463	0.0015	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—liver cancer	0.000462	0.0015	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—liver cancer	0.00046	0.0015	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—liver cancer	0.000458	0.00149	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—liver cancer	0.000458	0.00149	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—liver cancer	0.000458	0.00149	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—liver cancer	0.000442	0.00144	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—liver cancer	0.000438	0.00142	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—liver cancer	0.000426	0.00138	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—liver cancer	0.000424	0.00138	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—liver cancer	0.000424	0.00138	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—liver cancer	0.000415	0.00135	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—liver cancer	0.00041	0.00133	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—liver cancer	0.000396	0.00129	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—liver cancer	0.000384	0.00125	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—liver cancer	0.000383	0.00125	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—liver cancer	0.000379	0.00123	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—liver cancer	0.000368	0.0012	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—liver cancer	0.000367	0.00119	CcSEcCtD
Maprotiline—Rash—Epirubicin—liver cancer	0.000365	0.00119	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—liver cancer	0.000365	0.00119	CcSEcCtD
Maprotiline—Headache—Epirubicin—liver cancer	0.000363	0.00118	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—liver cancer	0.000354	0.00115	CcSEcCtD
Maprotiline—Nausea—Epirubicin—liver cancer	0.000344	0.00112	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—liver cancer	0.000341	0.00111	CcSEcCtD
Maprotiline—Rash—Doxorubicin—liver cancer	0.000338	0.0011	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—liver cancer	0.000338	0.0011	CcSEcCtD
Maprotiline—Headache—Doxorubicin—liver cancer	0.000336	0.00109	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—liver cancer	0.000318	0.00103	CcSEcCtD
Maprotiline—Nortriptyline—CYP2E1—liver cancer	9.95e-05	0.326	CrCbGaD
Maprotiline—Desipramine—CYP2E1—liver cancer	8.19e-05	0.268	CrCbGaD
Maprotiline—Imipramine—CYP2E1—liver cancer	6.95e-05	0.227	CrCbGaD
Maprotiline—Nortriptyline—ALB—liver cancer	5.47e-05	0.179	CrCbGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CD—liver cancer	1.69e-05	9.72e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SERPINE1—liver cancer	1.69e-05	9.71e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—liver cancer	1.69e-05	9.69e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—liver cancer	1.69e-05	9.68e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—liver cancer	1.69e-05	9.67e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TGFB1—liver cancer	1.68e-05	9.66e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—liver cancer	1.68e-05	9.64e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—PIK3CA—liver cancer	1.68e-05	9.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SERPINE1—liver cancer	1.68e-05	9.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—liver cancer	1.67e-05	9.61e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—liver cancer	1.66e-05	9.52e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—liver cancer	1.66e-05	9.51e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—MTHFR—liver cancer	1.66e-05	9.5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—HRAS—liver cancer	1.65e-05	9.49e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—STAT3—liver cancer	1.64e-05	9.42e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1B—liver cancer	1.63e-05	9.33e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARA—liver cancer	1.62e-05	9.32e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—liver cancer	1.61e-05	9.23e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—liver cancer	1.59e-05	9.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CASP3—liver cancer	1.59e-05	9.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL2—liver cancer	1.59e-05	9.13e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TGFB1—liver cancer	1.59e-05	9.12e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTM1—liver cancer	1.59e-05	9.11e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—liver cancer	1.58e-05	9.08e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—liver cancer	1.58e-05	9.05e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RAF1—liver cancer	1.57e-05	8.98e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—liver cancer	1.56e-05	8.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.55e-05	8.91e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—liver cancer	1.55e-05	8.9e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—liver cancer	1.55e-05	8.89e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—JUN—liver cancer	1.55e-05	8.88e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	1.54e-05	8.86e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RAF1—liver cancer	1.54e-05	8.84e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—liver cancer	1.54e-05	8.83e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RAF1—liver cancer	1.54e-05	8.82e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.54e-05	8.81e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RAF1—liver cancer	1.53e-05	8.79e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—liver cancer	1.53e-05	8.77e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MTOR—liver cancer	1.53e-05	8.77e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RAF1—liver cancer	1.53e-05	8.76e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—liver cancer	1.53e-05	8.75e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—liver cancer	1.52e-05	8.74e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—liver cancer	1.52e-05	8.73e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RAF1—liver cancer	1.51e-05	8.68e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—liver cancer	1.51e-05	8.64e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP1A1—liver cancer	1.5e-05	8.64e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MTOR—liver cancer	1.5e-05	8.63e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.5e-05	8.63e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MTOR—liver cancer	1.5e-05	8.61e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—liver cancer	1.5e-05	8.61e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.5e-05	8.61e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—liver cancer	1.5e-05	8.58e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MTOR—liver cancer	1.5e-05	8.58e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MTOR—liver cancer	1.49e-05	8.56e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—liver cancer	1.49e-05	8.56e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—liver cancer	1.48e-05	8.47e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MTOR—liver cancer	1.48e-05	8.47e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—liver cancer	1.48e-05	8.47e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—liver cancer	1.47e-05	8.45e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.46e-05	8.4e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.46e-05	8.38e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—liver cancer	1.46e-05	8.37e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.44e-05	8.24e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1B—liver cancer	1.43e-05	8.23e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—liver cancer	1.43e-05	8.22e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—liver cancer	1.43e-05	8.22e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—liver cancer	1.43e-05	8.19e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—liver cancer	1.43e-05	8.18e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—liver cancer	1.42e-05	8.17e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—liver cancer	1.42e-05	8.14e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.41e-05	8.1e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—liver cancer	1.41e-05	8.09e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—liver cancer	1.41e-05	8.09e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1B—liver cancer	1.41e-05	8.08e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—liver cancer	1.41e-05	8.07e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1B—liver cancer	1.4e-05	8.06e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—liver cancer	1.4e-05	8.05e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—liver cancer	1.4e-05	8.05e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1B—liver cancer	1.4e-05	8.03e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—liver cancer	1.4e-05	8.01e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.4e-05	8.01e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—liver cancer	1.39e-05	7.99e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—liver cancer	1.39e-05	7.98e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—liver cancer	1.39e-05	7.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1B—liver cancer	1.39e-05	7.95e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—liver cancer	1.39e-05	7.95e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—liver cancer	1.38e-05	7.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—liver cancer	1.38e-05	7.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—liver cancer	1.38e-05	7.93e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—liver cancer	1.38e-05	7.92e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—liver cancer	1.38e-05	7.91e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARA—liver cancer	1.38e-05	7.9e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—liver cancer	1.38e-05	7.89e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—liver cancer	1.37e-05	7.89e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—liver cancer	1.37e-05	7.88e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—liver cancer	1.37e-05	7.87e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—liver cancer	1.37e-05	7.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—liver cancer	1.37e-05	7.87e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—liver cancer	1.37e-05	7.86e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—liver cancer	1.37e-05	7.85e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—liver cancer	1.37e-05	7.84e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—JUN—liver cancer	1.37e-05	7.84e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—liver cancer	1.36e-05	7.82e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—liver cancer	1.36e-05	7.79e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—liver cancer	1.36e-05	7.78e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CTNNB1—liver cancer	1.35e-05	7.78e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—liver cancer	1.35e-05	7.76e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.35e-05	7.76e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—liver cancer	1.35e-05	7.74e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—liver cancer	1.35e-05	7.73e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—JUN—liver cancer	1.34e-05	7.71e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—liver cancer	1.34e-05	7.71e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—liver cancer	1.34e-05	7.71e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—JUN—liver cancer	1.34e-05	7.69e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—liver cancer	1.34e-05	7.68e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—liver cancer	1.34e-05	7.68e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—JUN—liver cancer	1.34e-05	7.67e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—liver cancer	1.33e-05	7.66e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.33e-05	7.65e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—JUN—liver cancer	1.33e-05	7.64e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CTNNB1—liver cancer	1.33e-05	7.63e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—liver cancer	1.33e-05	7.62e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CTNNB1—liver cancer	1.33e-05	7.61e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—liver cancer	1.32e-05	7.6e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1A—liver cancer	1.32e-05	7.6e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—liver cancer	1.32e-05	7.59e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CTNNB1—liver cancer	1.32e-05	7.59e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JUN—liver cancer	1.32e-05	7.57e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CTNNB1—liver cancer	1.31e-05	7.51e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—liver cancer	1.31e-05	7.51e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—liver cancer	1.31e-05	7.5e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—liver cancer	1.3e-05	7.48e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.3e-05	7.47e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—liver cancer	1.3e-05	7.46e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1A—liver cancer	1.3e-05	7.46e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—liver cancer	1.3e-05	7.45e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—liver cancer	1.3e-05	7.44e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1A—liver cancer	1.3e-05	7.43e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—liver cancer	1.29e-05	7.43e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK8—liver cancer	1.29e-05	7.41e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1A—liver cancer	1.29e-05	7.41e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—liver cancer	1.29e-05	7.39e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—liver cancer	1.28e-05	7.36e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ALB—liver cancer	1.28e-05	7.35e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1A—liver cancer	1.28e-05	7.34e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.27e-05	7.29e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK8—liver cancer	1.27e-05	7.28e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—liver cancer	1.27e-05	7.28e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.27e-05	7.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—liver cancer	1.26e-05	7.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK8—liver cancer	1.26e-05	7.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—liver cancer	1.26e-05	7.24e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK8—liver cancer	1.26e-05	7.23e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—liver cancer	1.26e-05	7.21e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—liver cancer	1.25e-05	7.19e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—liver cancer	1.25e-05	7.18e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK8—liver cancer	1.25e-05	7.16e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—liver cancer	1.24e-05	7.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—liver cancer	1.24e-05	7.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.24e-05	7.12e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.24e-05	7.09e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—liver cancer	1.22e-05	7.02e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ALB—liver cancer	1.21e-05	6.93e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—liver cancer	1.2e-05	6.88e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—liver cancer	1.2e-05	6.87e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—liver cancer	1.19e-05	6.85e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—liver cancer	1.18e-05	6.78e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—liver cancer	1.18e-05	6.76e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.17e-05	6.74e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—liver cancer	1.17e-05	6.72e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—liver cancer	1.17e-05	6.71e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—liver cancer	1.17e-05	6.7e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—liver cancer	1.16e-05	6.68e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—liver cancer	1.16e-05	6.67e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—liver cancer	1.16e-05	6.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—liver cancer	1.16e-05	6.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—liver cancer	1.15e-05	6.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—liver cancer	1.15e-05	6.61e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—liver cancer	1.15e-05	6.59e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—liver cancer	1.15e-05	6.58e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—liver cancer	1.14e-05	6.55e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—liver cancer	1.14e-05	6.53e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—liver cancer	1.13e-05	6.49e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—liver cancer	1.1e-05	6.34e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—liver cancer	1.1e-05	6.3e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—liver cancer	1.09e-05	6.28e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—liver cancer	1.09e-05	6.24e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—liver cancer	1.08e-05	6.2e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—liver cancer	1.08e-05	6.18e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.08e-05	6.18e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—liver cancer	1.07e-05	6.17e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—liver cancer	1.07e-05	6.16e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—liver cancer	1.07e-05	6.15e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—liver cancer	1.07e-05	6.14e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—liver cancer	1.07e-05	6.13e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—liver cancer	1.07e-05	6.12e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—liver cancer	1.06e-05	6.08e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—liver cancer	1.06e-05	6.07e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—liver cancer	1.06e-05	6.07e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—liver cancer	1.06e-05	6.06e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—liver cancer	1.04e-05	5.95e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALB—liver cancer	1.02e-05	5.87e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—liver cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—liver cancer	1.01e-05	5.82e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—liver cancer	9.98e-06	5.73e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—liver cancer	9.96e-06	5.71e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—liver cancer	9.92e-06	5.7e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—liver cancer	9.89e-06	5.68e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—liver cancer	9.8e-06	5.62e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—liver cancer	9.77e-06	5.6e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—liver cancer	9.35e-06	5.36e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—liver cancer	9.32e-06	5.35e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—liver cancer	9.17e-06	5.26e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—liver cancer	9.15e-06	5.25e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—liver cancer	9.12e-06	5.23e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—liver cancer	9.09e-06	5.22e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—liver cancer	9.03e-06	5.18e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—liver cancer	9.01e-06	5.17e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—liver cancer	9e-06	5.17e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—liver cancer	8.88e-06	5.1e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—liver cancer	8.87e-06	5.09e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—liver cancer	8.85e-06	5.08e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—liver cancer	8.82e-06	5.06e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—liver cancer	8.79e-06	5.05e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—liver cancer	8.71e-06	5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—liver cancer	8.62e-06	4.95e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—liver cancer	8.62e-06	4.95e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—liver cancer	8.48e-06	4.87e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—liver cancer	8.46e-06	4.86e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—liver cancer	8.44e-06	4.84e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—liver cancer	8.41e-06	4.83e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—liver cancer	8.33e-06	4.78e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—liver cancer	8.25e-06	4.73e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—liver cancer	8.12e-06	4.66e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—liver cancer	8.1e-06	4.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—liver cancer	8.07e-06	4.63e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—liver cancer	8.05e-06	4.62e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—liver cancer	7.97e-06	4.57e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—liver cancer	7.61e-06	4.37e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—liver cancer	7.49e-06	4.3e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—liver cancer	7.47e-06	4.29e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—liver cancer	7.45e-06	4.27e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—liver cancer	7.42e-06	4.26e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—liver cancer	7.35e-06	4.22e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—liver cancer	6.9e-06	3.96e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—liver cancer	6.5e-06	3.73e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—liver cancer	5.63e-06	3.23e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—liver cancer	5.51e-06	3.16e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—liver cancer	5.31e-06	3.05e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—liver cancer	4.5e-06	2.58e-05	CbGpPWpGaD
